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Protease encapsulation and its targeted release in thrombi may contribute to the reduction of haemorrhagic complications of
thrombolysis. We aimed to prepare sterically stabilized trypsin-loaded liposomes (SSLT) and characterize their structure and
fibrinolytic efficiency. Hydrogenated soybean phosphatidylcholine-based SSLT were prepared and their structure was studied by
transmission electron microscopy combined with freeze fracture (FF-TEM), Fourier transform infrared spectroscopy (FT-IR),
and small-angle X-ray scattering (SAXS). Fibrinolytic activity was examined at 45, 37, or 24∘C on fibrin or plasma clots with
turbidimetric and permeation-driven lysis assays. Trypsin was shown to be attached to the inner surface of vesicles (SAXS and
FF-TEM) close to the lipid hydrophilic/hydrophobic interface (FT-IR). The thermosensitivity of SSLT was evidenced by enhanced
fibrinolysis at 45∘C: time to reduce the maximal turbidity to 20% decreased by 8.6% compared to 37∘C and fibrin degradation
product concentration in the permeation lysis assay was 2-fold to 5-fold higher than that at 24∘C. SSLT exerted its fibrinolytic action
on fibrin clots under both static and dynamic conditions, whereas plasma clot dissolution was observed only in the permeation-
driven assay. The improved fibrinolytic efficiency of SSLT under dynamic conditions suggests that they may serve as a novel
therapeutic candidate for dissolution of intravascular thrombi, which are typically exposed to permeation forces.
1. Introduction
Thrombolysis based on enzymatic dissolution of fibrin is
currently the first-line treatment of ischemic stroke as well
as certain selected cases of acute myocardial infarction [1, 2].
Most of the fibrinolytic agents are plasminogen activators,
which can be classified as “indirect fibrinolytics,” because
their enzymatic action is directed towards plasminogen,
while, in contrast, fibrinolytics such as plasmin and its
derivatives degrade fibrin without any intermediate step
of plasminogen activation and are therefore designated as
“direct fibrinolytics.” Systemic (intravenous) administration
of indirect fibrinolytics is accompanied by frequent bleeding
side effects related to the large excess of activator at its
therapeutic dose over the inhibitor capacity of blood plasma
[3]. In contrast, locally administered plasmin exerts its
fibrinolytic action in fibrin-bound form being protected from
its main inhibitor (𝛼2-plasmin inhibitor) but is immediately
inactivated when entering the circulation, thus preventing
bleeding at remote sites of vascular injury (reviewed in
[4]). However, catheter directed thrombolysis combined with
systemic thrombolysis may be associated with higher risk of
pulmonary embolism or intracranial haemorrhage compared
to systemic thrombolysis alone [5].
Nanomedicine offers approaches for noninvasive and
rapid thrombolytic treatment, with the hope of further
reducing the morbidity and mortality of occlusive cardiovas-
cular events. Being encapsulated into liposomes, drugs are
preserved from metabolization prior to reaching target tis-
sues, and simultaneously they minimize exposure of healthy
tissue to the encapsulated drug during its circulation in the
blood. The possibility to target liposomes helps in localizing
sufficient quantities of thrombolytic agents to the desired
thrombus. In vivo results show strong evidence that external
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targeting is superior to passive targeting of highly stable
long-circulating drug formulations. A promising alternative
for external targeting is achieved by temperature-triggered,
localized intravascular drug release from thermosensitive
liposomes with focused heating ([6], reviewed in [7]).
Trypsin could be a novel candidate for being a liposome-
encapsulated thrombolytic drug because of its high fibri-
nolytic efficiency [8] and about 3.5 times lower molecular
mass compared to that of plasmin allowing higher encapsu-
lated enzyme concentration. If administered in a plasma envi-
ronment, encapsulated trypsin is protected against plasma
inhibitors, the most abundant of which is 𝛼1-PI (𝛼1-protease
inhibitor). However, in contrast to plasmin and tPA, trypsin
lacks any structural domains for recognition and specific
binding to fibrin. Thus, an alternative targeting strategy is
required to allow for a local proteolytic action of trypsin
in thrombi. Such an option is offered by the temperature-
dependent release of the enzyme from the thermosensitive
liposomes developed and characterized in the current study,
which in vivo could be achieved with focused ultrasound
thermal effects. Following the local release of trypsin in
thrombi, the availability of the fibrin substrate will protect
the enzyme from inactivation by𝛼1-PI, similarly to the fibrin-
mediated protection of other proteases (plasmin and PMN-
elastase) against plasma protease inhibitors [9].
The purpose of our work was to prepare trypsin-loaded
PEGylated liposomes and characterize them in terms of their
structure and proteolytic efficiency in pure fibrin, as well as
in plasma environment.
2. Materials and Methods
2.1. Proteins and Reagents. If not otherwise indicated, exper-
iments were performed in HEPES buffered saline (HBS,
10mM HEPES, 150mM NaCl, pH 7.4). Porcine trypsin and
bovine thrombin were purchased from Serva Electrophoresis
GmbH (Heidelberg, Germany) and the latter was further
purified as described in [10] yielding a preparation with
specific activity of 2100 IU/mg.Thrombin activity of 1 IU/mL
was considered equivalent to approximately 10.7 nMby active
site titration [11]. Fibrinogen (human, plasminogen-depleted)
was from Calbiochem (San Diego, CA, USA). Hydrogenated
soybean phosphatidylcholine, cholesterol, distearoyl-phos-
phatidylethanolamine PEG2000, and cholesterol sulphate
were acquired from Avanti (Birmingham, AL, USA). DPH
(1,6-diphenyl-1,3,5-hexatriene) and fluorescamine were from
Sigma-Aldrich Kft. (Budapest, Hungary) and Spectrozyme-
PL (H-D norleucylhexahydrotyrosyl-lysine-p-nitroanilide)
was from Sekisui Diagnostics (Pfungstadt, Germany). Cit-
rated, fresh frozen plasma (fibrinogen concentration: 2.35 g/l)
was obtained from the Hungarian Blood Supply Service
(Budapest, Hungary).
2.2. Preparation of Trypsin-Loaded Liposomes. Trypsin-load-
ed (SSLT) and empty (SSL) sterically stabilized liposomes
consisting of hydrogenated soybean phosphatidylcholine,
cholesterol, distearoyl phosphatidylethanolamine PEG2000,
and cholesterol sulphate at a molar ratio of 15 : 4 : 1 : 1 were
prepared by thin-layer evaporation method as follows. Con-
stituents weremixed and dissolved in a chloroform/methanol
mixture (95 : 5 volume ratio) at a total phospholipid concen-
tration of 34mg/ml. Evaporation of the organic solvent was
facilitated by a vacuum pump (20mbar, at 24∘C, overnight).
The lipid film was hydrated at room temperature with HBS
for preparing empty liposomes or 0.1mM HCl in distilled
water containing 10mg/ml porcine trypsin for trypsin-loaded
liposomes and stirred for 10min at 1200 rpm. Formation of
unilamellar vesicles was promoted by sonication (three cycles
of 30 s at 50 watt, 20 kHz in a Branson Sonifier 250, Branson
UltrasonicsCorp., Danbury, CT,USA) followed by ten freeze-
thaw cycles (−78∘C; +42∘C). SSLT was then extruded through
a 100 nm pore diameter polycarbonate filter in a LiposoFast
mini-extruder (Avestin Inc., Ottawa, Canada). Nonencapsu-
lated trypsin and lipid debris were removed from supernatant
by centrifugation (3 times for 15min at 133,000𝑔) with a
Beckman Airfuge 340401 ultracentrifuge. The sediment was
resuspended in HBS yielding a liposome preparation of
neutral pH, with trypsin encapsulated in its inactive form
due to the low pH inside of the enzyme loaded vesicles. The
concentration of phospholipids in the SSLT suspension was
determined with the fluorescent probe DPH [12] yielding
a concentration of about 30mg/ml. Changes in enzyme
activity of the encapsulated trypsin were monitored daily
on the chromogenic small peptide substrate Spectrozyme-PL
(SpPL) at 405 nm after lysing liposomes by stirring together
with 2.5 v/v% Triton X-100 for ten seconds at 1200 rpm. SSLT
was stored at 4∘C until use.
2.3. Dynamic, Permeation-Driven Lysis of Fibrin and Plasma
Clots. In order to examine the fibrinolytic activity of our
liposome preparation under dynamic conditions, fibrin and
plasma permeation studies were performed at 24 and 45∘C.
The inner surfaces of 5ml pipette tips (Finntip, Thermo
Scientific, Budapest, Hungary) were precoated with 1 g/l
fibrinogen for 3 h and then air-dried [13]. Fibrin clots were
prepared fromfibrinogen at 7.5𝜇Mclottedwith 16 nM throm-
bin in the fibrinogen-coated pipette tips. Plasma clots were
prepared from citrated, fresh frozen plasma supplemented
with fibrinogen to 7.5 𝜇M final concentration and CaCl2 to
12.5mM and filled in the tips. After 70min of incubation
at 37∘C, stable clots were washed thoroughly with HBS
to remove unclotted fibrinogen and other plasma proteins.
Trypsin-loaded liposomes (50𝜇l) containing phospholipid
at 5mg/ml and enzyme activity corresponding to that of
300 nM free trypsin, empty liposomes, or HBS were layered
over clots of 200𝜇l volume. After the entry of the liposomal
suspension into the clots, HBS was added and continuously
supplemented to keep a constant hydrostatic pressure over
the clots. The pipette tips were kept at 24 or 45∘C during
the lytic process. Consecutive fractions of 50𝜇l were then
collected and their protein concentration was determined by
the fluorescamine method [14] and plotted against the eluted
volume. Fractions with the highest protein content were
analyzed with SDS polyacrylamide gel electrophoresis (SDS
PAGE) in 4–15% gradient gels under nonreducing conditions,
followed by visualization of protein bandswith silver staining.
BioMed Research International 3
2.4. Lysis of Fibrin and Plasma Clots in a Turbidimetric Assay.
Two different experimental setups were designed to measure
the fibrinolytic effectiveness of our liposomes under static
conditions. First, fibrinogen at 7.5𝜇M or plasma supple-
mentedwith fibrinogen (7.5 𝜇M) and calcium (12.5mM)were
clotted with thrombin (20 nM) at 37∘C in 96-well microtiter
plates. Clot dissolution was started by layering 50 𝜇l of SSLT
(or empty liposomes or HBS) containing phospholipid at
about 30mg/ml and enzyme activity corresponding to that of
1.8 𝜇M trypsin over the clot (“extrinsic lysis” assay), followed
by measuring the light absorbance at 340 nm at 37∘C with a
Zenyth 200rt microplate spectrophotometer (Anthos Labtec
InstrumentsGmbH, Salzburg, Austria) and in parallel at 45∘C
with a CLARIOstar microplate reader (BMG LABTECH
GmbH, Ortenberg, Germany). In a second (“intrinsic lysis”)
setup, fibrinogen and plasma clots were prepared as above,
but prior clotting SSLT (or SSL) was homogeneously dis-
persed in the clotting mixture at 3mg/ml final phospholipid
concentration and 180 nM trypsin. The clotting and the clot
dissolution phases were monitored by measuring the light
absorbance at 37∘C and 45∘C in parallel. The CLARIOstar
microplate reader was used in an orbital averaging mode.
Using this mode, the measurement takes place on an orbit
with definable diameter within each well. It results in higher
absorbance values compared to the measurement using a
Zenyth 200rt microplate spectrophotometer in a normal
mode, when one point ismeasured in themiddle of each well.
Therefore, data gained at 37∘C with the Zenyth microplate
reader were multiplied by a factor of 2.41 to be comparable
with those gained at 45∘C with the other instrument. For
comparison of lytic rates of the two static assays, the time
needed to reduce the turbidity of the clots by a given fraction
of the maximal value (𝑇20, 𝑇50, and 𝑇80 to reach 0.8, 0.5, and
0.2𝐴max, resp.) was calculated as a quantitative parameter of
fibrinolytic activity. The curve analyzing process and statis-
tical comparison of the 𝑇 values with Kolmogorov-Smirnov
test were performed inMatlab R2016a (TheMathWorks, Inc.,
Natick, MA, USA).
2.5. Transmission Electron Microscopy Combined with Freeze
Fracture (FF-TEM). A 1-2 𝜇l droplet of SSLT or SSL sus-
pension was used for freeze fracturing. The samples were
pipetted to the golden sample holder and rapidly frozen
in the mixture of liquid and solid Freon, cooled by liquid
nitrogen. Fracturing was performed at 173 K in a freeze
fracture device (BAF 400D, Balzers AG, Liechtenstein). The
fractured surfaces were etched for 30 s at 173 K and then
shadowed by platinum and covered with carbon.The replicas
obtained were washed with surfactant and water and were
finally transferred to 200-mesh copper grids. The electron
micrographs were made in a Philips Morgagni 268D electron
microscope.
2.6. Fourier Transform Infrared Spectroscopy (FTIR). For
FTIR spectroscopic study, the attenuated total reflection
(ATR) technique was used, having a penetration depth of
infrared light in the samples in the order of one micrometer,
so the investigation in bulk aqueous phase was possible, too.
ATR-FTIR spectroscopic measurements were carried out
by means of a Varian 2000 (Scimitar Series) FTIR spec-
trometer fitted with a diamond attenuated total reflection
cell (Specac’s “Golden Gate” single reflection ATR unit with
active area of 600 × 600 𝜇m2). SSLT (or SSL) suspension
(5 𝜇l) was spread onto the diamond ATR surface. Room
temperature spectra (128 scans, resolution of 2 cm−1) were
recorded both as suspension using a cap to avoid sample
drying and as dry films after slow evaporation of the buffer
solvent under ambient conditions. ATR correction was exe-
cuted after each data collection. All spectral manipulations
were performed usingGRAMS/32 software package (Galactic
Industries Incorporation, USA).
2.7. Small-Angle X-Ray Scattering (SAXS). Small-angle X-ray
scattering measurements were performed using CREDO, an
in-house transmission geometry setup [15]. SSLT and SSL
samples (at 20mg/ml phospholipid) were filled into thin-
walled quartz capillaries of 1.2mm average outer diameter.
After proper sealing, these were placed in a temperature-
controlled aluminium block, which was inserted into the
vacuum space of the sample chamber. Measurements were
done using monochromatized and collimated Cu K𝛼 radia-
tion (0.1542 nm wavelength), and the scattering pattern was
recorded in the range of 0.23–1.03 nm−1 in terms of the
scattering variable (defined as 𝑞 = (4𝜋 sin 𝜗)/𝜆, where 2𝜗
is the scattering angle and 𝜆 is the X-ray wavelength). The
total measurement times were 7.5 hours for each sample.
In order to assess sample and instrument stability during
the experiment, the exposures were made in 5-minute units,
with frequent sample change and reference measurements.
The same measurement protocol was used in our previous
study executed on artificial nanoerythrosomes [16]. These
individual exposures were corrected for beam flux, geometric
effects, sample self-absorption, and instrumental background
and calibrated into physical units of momentum transfer
(𝑞, nm−1) and differential scattering cross section (absolute
intensity, cm−1 × sr−1). The averages of all the corrected
and calibrated scattering patterns for each sample were
azimuthally averaged to yield single one-dimensional scatter-
ing curves for each sample [17–19].
3. Results and Discussion
3.1. Evaluating the Fibrinolytic Function of 𝑆𝑆𝐿𝑇. According
to the trypsin activity measurements, enzyme activity of our
SSLT preparation on the first day (100%)was equivalent to the
activity of 1.8𝜇M free trypsin.Then, following an initial drop
of 30% during the first 3 days, it remained unchanged for 10
days stored at 4∘C (data not shown).
Thefibrinolytic activity of SSLT was tested under dynamic
conditions with permeation of fibrin and plasma clots at
room temperature and 45∘C in parallel to test the thermosen-
sitivity of the liposome vehicle construct. Trypsin-loaded
liposomes were layered over the surface and after their entry
into the clotsHBSwas added and continuously supplemented
to keep a constant hydrostatic pressure over the clots. The
eluted fluidwas collected in fractions and analyzed for protein
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Figure 1: Permeation-driven lysis of fibrin and plasma clots. SSLT (solid lines) or HBS (dashed lines) was layered to the surface of fibrin (a)
or plasma (b) clots; thereafter a constant hydrostatic pressure was maintained over the clots and the eluted fluid was collected in fractions of
50 𝜇l each, in which the protein content was measured and is shown as mean ± SEM (𝑛 = 3). Red and blue colours indicate clot lysis at 45∘C
and 24∘C, respectively.
content, indicating the release of soluble fibrin degradation
products (Figure 1).
Elevated temperature during the lytic phase markedly
enhanced the lytic efficiency of the trypsin-loaded liposomes.
Close to the phase transition temperature enhanced area fluc-
tuations and increased lateral compressibility of the liposome
membrane lead to increased likelihood of spontaneous lipid
pore formation and therefore to permeation events [20] and
the consequent release of the encapsulated enzyme. Thus,
increased lytic efficiency at elevated temperatures proves that
the applied liposome is a thermosensitive construct.Theupper
limit of mild hyperthermia during cancer therapy is 45∘C,
while higher temperatures are used for ablation techniques
causing serious damage in the tumor tissue, but cells with
normal vascularization and normal heat-shock protection
mechanismsmight be safely subjected to a thermal treatment
of 45∘C [21, 22]. This local thermal effect could be achieved
in thrombi with high intensity focused ultrasound with con-
trolled and selected parameters. The conformal microwave
array applicators are also potential hyperthermia applications
that may be suitable for heat-assisted thrombolysis [22–25].
Nevertheless, (i) the drug release at 24∘C, (ii) the slightly
elevated level of detectable protein in fractions of the control
sample at 45∘C in a fibrin environment (Figure 1(a)), and
(iii) the lower detectable protein concentrations in fractions
collected during plasma permeation with SSLT (Figure 1(b))
need further consideration.
(i) Since SSLT was stored at 4
∘C before and during
trypsin activity measurements, the observed stability of
the encapsulated enzyme provides information about drug
retention capacity at low temperatures. Therefore, it cannot
be excluded that at 24∘C protein leakage increases from
SSLT due to changes of the organization in the SSLT double
layer. Furthermore, despite the fact that PEGylation is the
most common method for vesicle stabilization and prevent-
ing interactions between the particle surface and plasma
proteins, interactions between PEGylated nanoparticles and
albumin, fibrinogen, IgG, and apolipoproteins have been
reported [26]. Moreover, interactions of antimicrobial [27],
cytoskeletal [28, 29], and other proteins (calponin [30]) with
lipid vesicles have been found to cause vesicle leakage. Since
fibrinogen is known to bind phospholipids [31, 32], drug
release from SSLT due to interaction with fibrin(ogen) is also
a plausible explanation for detectable fibrin degradation at
24∘C during fibrin permeation by trypsin-loaded vesicles.
(ii)Mild disintegration at 45∘C due to less stable structure
of fibrin clots compared to that of plasma clots containing
calcium and FXIII (Figure 1(b), red, dashed lines) may lead
to the constant, slightly elevated level of detectable protein
in fractions of the control sample in the case of fibrin clots
(Figure 1(a), red, dashed lines).
(iii) Lower protein concentrations of the eluted fractions
in the plasma clot permeation (Figure 1(b)) compared to
the fibrin clot permeation (Figure 1(a)) are presumably the
consequence of the plasma clot being more resistant to lysis
compared to the fibrin clot due to the possibility to form
cross-links during the clotting phase. Furthermore, previous
studies have shown that 𝛼1-antitrypsin is noncovalently
bound to fibrin clots prepared from plasma, preserving its
serine protease inhibitor activity despite extensive washing
[33]. The presence of such an effective inhibitor of trypsin
may also lead to decreased fibrinolytic efficiency of SSLT in
plasma clots.
SDS polyacrylamide gel electrophoresis was performed to
examine the protein size distribution of the fractions with the
highest protein concentrations in both cases (Figure 2).
A plasmin-like degradation pattern of fibrin [34] was
observed with different types of fibrin degradation products,
which evidenced that the protein content of fractionswith the
highest protein concentrations originated exclusively from
fibrin degraded by trypsin. It should be noted that no fibrin
degradation was found after layering empty liposomes over
the fibrin or plasma clots.
In addition to the permeation studies, the fibrinolytic
activity of SSLT was investigated under static conditions
in “extrinsic lysis” assay by liposomes layered over and in
“intrinsic lysis” assay by liposomes incorporated into fibrin
and plasma clots at 37 and 45∘C. In the extrinsic lysis setup,
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Figure 2: SDS polyacrylamide gel electrophoresis of protein fractions with the highest concentrations collected during fibrin and plasma clot
permeation by SSLT. Three parallel fractions collected during fibrin (panel (a), fraction number 2) and plasma (panel (b), fraction number
3) clot permeation with SSLT.
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Figure 3: Lysis of fibrin by SSLT layered on the clot surface or homogeneously dispersed in the clots.The liposomal solution was layered over
preformed clots (a) or added to fibrinogen before the clotting phase (b) and thereafter formation and/or dissolution of fibrin were followed
as changes in absorbance at 340 nm shown as mean (solid lines) ± SEM (dotted lines) of three measurements. Red and blue colours indicate
clot lysis at 45∘C and 37∘C, respectively.
the complete dissolution of fibrin clot was achieved in 4 h. No
significant differencewas found between lysis times at the two
different temperatures applied (Figure 3(a) and Table 1).
In the “intrinsic lysis” setup, SSLT was incorporated into
the clots during the clotting phase. Then, clots were let to
dissolve on their own at different temperatures. The time
needed for complete dissolution was about 2–2.5 hours at
both examined temperatures, although a significant decrease
in𝑇80 (time needed to reduce the turbidity of the clots by 80%
of𝐴max) was observed at 45
∘C, implying faster trypsin release
at the higher temperature again (Figure 3(b) and Table 1).
Under static conditions, there was no change in the
absorbance values after the clotting phase in the control fibrin
and plasma clots treated with HBS or SSL or in the plasma
clots with HBS, SSL, or SSLT (data not shown).
The failure to dissolve plasma clots under static con-
ditions can be traced back to the effect of 𝛼1-antitrypsin
retained in the clot. Furthermore, the SSLT suspension was
diluted to a greater extent in the intrinsic lysis setup compared
Table 1: Lysis times needed to dissolve fibrin clots by 20, 50, or
80%. Mean values ± SEM are shown (𝑛 = 3). Asterisk indicates
statistical significance between the 𝑇
80
values measured at the two
temperatures at 𝑝 < 0.05 according to Kolmogorov-Smirnov test.
𝑇
20
(min) 𝑇
50
(min) 𝑇
80
(min)
Extrinsic lysis
37∘C 21.23 ± 6.96 89.75 ± 13.50 190.16 ± 9.02
45∘C 42.99 ± 6.64 72.77 ± 14.71 167.71 ± 17.80
Intrinsic lysis
37∘C 131.44 ± 4.39 165.80 ± 4.70 192.24 ± 5.06
45∘C 133.71 ± 1.15 156.41 ± 2.08 175.78∗ ± 2.88
to the permeation of plasma clots; thus the concentration of
trypsin released from liposomes was not sufficiently high to
counteract its inhibitor(s). Finally, the permeation pressure
in the dynamic assay is an additional factor contributing to
the enhanced release of the entrapped enzyme compared to
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Figure 4:The surface morphology of the trypsin-free ((a) and (b)) and trypsin-loaded ((c) and (d)) vesicles by freeze fracture TEM. (a)Three
types of fractures can be observed: (A) convex fractured surfaces of the vesicles protruding from the aqueous medium, (B) concave areas of
the imprints of vesicles broken out, and (C) bottom parts of remaining vesicles broken through entirely. (b) The inner surface of a vesicle,
broken through entirely, is typically smooth. All three types of fractured surfaces are observed in the trypsin-loaded vesicles (c), but the inner
surface contains also closely packed grains (d).
the liposomes stationary incorporated into the clot.The heat-
dependence of the trypsin release from SSLT was much less
pronounced and observed only in the late stage (𝑇80, Table 1)
of the static lysis assays, probably due to the smaller difference
between the two temperatures applied.
The large difference in the time needed for total clot
dissolution during surface (about 4 h), and inner (about 2 h)
dissolution despite the tenfold liposome concentration in
the former case is not unexpected. A similar difference is
observed in the fibrinolytic potency of plasmin layered over
fibrin and incorporated into fibrin clots; about a 100-fold
higher enzyme concentration is needed to achieve a com-
parable lysis rate from the surface than with clot-entrapped
plasmin [35, 36].
3.2. Structural Characterization of 𝑆𝑆𝐿𝑇. Themethod of TEM
combined with freeze fracture provides an excellent tool to
visualize the internal structure of vesicle systems of sizes
spanning from nanometers up to several micrometers [37].
The typical fractured surfaces of the nearly spherical vesicles
are shown on Figure 4(a). Apart from the convex fractured
surfaces of the vesicles protruding from their flat neigh-
bourhood (“A”) (corresponding to the original, aqueous
medium) we can observe the concave imprints of vesicles
broken out entirely from the medium (“B”). These two types
of fractured creations feature sharp contours. The third type
of characteristic fractured surfaces represents vesicles that
are broken through (“C”), leaving their bottom parts in
the medium. Instead of being sharp, the contours of these
are rather wide, corresponding to the wall thickness of the
vesicles.
Taking a closer look at the electron micrographs, we
can see that the outer surfaces of the vesicles are smooth
(Figure 4(a)). The limited roughness of these areas, and also
that of the inner surface of the remaining vesicle part, is
the consequence of the platinum grains formed during the
shadowing procedure, with a mean size of approx. 1-2 nm
(Figure 4(b)).
In the trypsin-containing vesicles, a similar surface pat-
tern can be observed in the outer convex and concave
surfaces (Figure 4(c)), but a distinct morphological feature
emerges in the third type of fracturing. The fractured surface
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Figure 5: Dry film spectra of trypsin-loaded (SSLT) and empty
(SSL) liposomes.
morphology of the loaded vesicles exhibits a bit higher
surface roughness: in thematrix around the vesicles the grain
size is about 2 ± 1 nm, while inside it is about 4 ± 1 nm as seen
in highermagnification image (Figure 4(d)).This observation
indicates that the trypsin molecules are attached to the inner
surface of the vesicles and are presumably not dispersed in
their inner/aqueous core.
IR spectroscopy is suitable to reveal possible enzyme-
lipid interaction by analysis of small spectral changes (band
position and intensity) of both lipid- and enzyme-related IR
bands. Figure 5 shows the ATR-FTIR spectra of empty and
trypsin-loaded liposomes recorded as dry films (after slow
evaporation of buffer solvent on the top of the diamond ATR
element).
Subtracting the spectra reveals the presence of amide
I and amide II bands around 1653 and 1547 cm−1, respec-
tively, corresponding to the presence of trypsin in trypsin-
loaded liposomes (Figure 6, SSLT spectrum). FTIR spec-
troscopy is widely applied to study protein secondary
structure and aggregation. In particular, the amide I band
(1700–1600 cm−1), correspondingmainly to the C=O stretch-
ing vibration of the peptide bond (∼80%), is sensitive to the
protein backbone conformational changes. Figure 6 shows
the amide I spectral region of trypsin spectra before (in
solution) and after encapsulation in liposomes. Trypsin is
classified as a “𝛽-protein” with dominant content of 𝛽-sheet
and 𝛽-turn conformations [38]. After encapsulation, the
relative amount of 𝛽-sheet conformers is slightly decreased,
while the band component corresponding to turns and 𝛽-
turns structure is slightly increased, reflected also in the shape
of the amide I band envelope.
To get information about the spectral changes linked to
the lipid molecules/bilayer, spectra recorded as suspension
were analyzed after buffer subtraction. The C-H stretching
region of the IR spectra (3020–2800 cm−1) involved mostly
the fatty acyl chains of the lipids (not shown). No differences
were observed for trypsin-loaded and empty liposomes,
suggesting that the order/disorder of the acyl chains remained
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Figure 6: Amide I spectral region of trypsin before (green) and
after (red) encapsulation in liposomes.The second derivatives of the
measured spectra were obtained by the Savitzky-Golay method (3rd
grade polynomial, 5 smoothing points).
intact. Concerning the lipid head group spectral region
(1800–900 cm−1), no changes in the phosphate vibrations
(]asPO2
− at 1234 cm−1, ]sPO2
− at 1088 cm−1, and ]R-O-P-
O-R󸀠 around 1070 cm−1) and in the antisymmetric C-N+
stretching vibrations (971 cm−1) of the choline groups could
be revealed.
The lipid carbonyl ester group is situated in the interfacial
region of the lipid bilayer and is a potentialH-bond formation
site. In highly hydrated phospholipid bilayers, this band splits
in two overlapping components: a high wavenumber band
around 1742 cm−1 of the non-hydrogen-bonded C=O groups
and a low wavenumber band around 1728 cm−1 due to the
hydrogen bonding of the C=O groups [39]. Detailed analysis
of the ]C=O band around 1737 cm−1 (Figure 7) indicated an
increase of the relative amount of H-bonded C=O subpopu-
lation: 𝐴 (]C=O H-bonded)/𝐴 (]C=O free) from 2.5 for SSL
to 5.2 for SSLT. These data suggested that trypsin was located
close to the lipid hydrophilic/hydrophobic interface driven by
weak interaction (H-bonds).
In summary, the IR spectroscopic data evidence that the
presence of trypsin molecules does not distort the acyl chain
order of the lipid bilayers composing the liposomes despite
the weak interaction-driven (H-bonds) location of the encap-
sulated trypsin close to the lipid hydrophilic/hydrophobic
interface.
Scattering techniques, especially small-angle X-ray scat-
tering (SAXS), are a powerful tool for identifying vari-
ous structural forms on the nanometer scale. To follow
the trypsin-induced changes in the layer structure of the
liposomes, SAXS measurements were performed. The one-
dimensional scattering patterns of the empty and trypsin-
loaded vesicles are shown in Figure 8. The scattering in
the initial range of the variable is intense and decreases
monotonously in both systems. This pattern originates from
the scattering of domains spanning a size range of several, up
to hundreds of nanometers. The two vesicle systems exhibit
8 BioMed Research International
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Figure 7: Lipid ester carbonyl stretching band region for empty (SSL) and trypsin-loaded (SSLT) liposomes. The solid black lines are the
measured spectra; the blue and the red lines are the fitted bands corresponding to intact and H-bonded C=O groups, respectively. The green
band component can be attributed to residual water (after subtraction) and to amide I band positions for curve fitting using the second
derivative; band shapes were approximated by Lorentzian functions. The intensities and the bandwidth of each component were optimized
according to a𝜒2minimization procedure.The relative contribution of each of the particular components was calculated from their integrated
areas in the best fit.
a similar scattering pattern with a broad peak in the 𝑞-range
from 0.4 to 2 nm−1, which can be attributed to the scattering
of the lipid bilayers, known as a form factor of the bilayer.
However, there is a slight but important difference between
the curves: the local minimum of the trypsin-containing
vesicle is not as deep as in the case of empty vesicles.
The scattering of trypsin in its solvated form shows a
monotonously decreasing SAXS pattern that is typically seen
in the scattering of uncorrelated, nearly globular particles
and corresponds to the nearly spherical shape of the trypsin
molecule with a 3 nm diameter (Figure 8).
The SAXS curve of the trypsin-containing vesicle can
be interpreted to the first approximation as the sum of the
contributions of the empty vesicle and the trypsin. There is a
slight difference, however, between the generated composite
and the measured scattering of SSLT curves (Figure 8). The
difference is significant in the regime of the form factor, indi-
cating the change in the bilayer structure and the association
between the bilayer and the protein.
The scattering pattern of SSLT can be fully reconstructed
by a spherical shell model, enabling an approximate descrip-
tion of the layer structure (see Supplementary Material
available online at https://doi.org/10.1155/2017/5130495). The
model for the least-squares fitting of the bilayer scattering
involves two identical, symmetrically placed Gaussian func-
tions for the two head group regions, one Gaussian for the
carbon chain region and two independent Gaussians for the
guestmolecules on the inner and outer side of the bilayer.The
size distribution of the vesicles is assumed to be Gaussian.
The best fit (SupplementaryMaterial) yields an asymmet-
ric distribution in the head region of vesicle bilayer; therefore
we may conclude that the protein molecules localize close
to the head region. The thickness of the inner region of
guest molecules (rich in trypsin) can be approximated by
10−1
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Figure 8: The one-dimensional scattering patterns of liposomes
with (red) and without (green) trypsin. The scattering of trypsin
in free solution (blue) and the curve generated as a sum of the
scattering of empty liposomes and solved trypsin (cyan) are also
shown.
the sum of the radial displacement of the maximum of the
corresponding Gaussian and its half width at half maximum
(HWHM) which is 3.73 nm + 1.74 nm ≈ 5.5 nm.The SAXS fit
has been executed without any a priori assumptions and the
results are in agreement with those obtained by IR, namely,
the fact that trypsin is located at the inner leaflet of bilayer in
the vicinity of the lipid head group.
4. Conclusions
We have developed a phospholipid-based thermosensitive
nanocarrier, in which trypsin is attached to the inner leaflet
of the bilayer shell of the liposome. Our findings also
BioMed Research International 9
represent a unique physicochemical description of a protein
encapsulated in a lipid vesicle and are important in order
to appreciate that the enzyme action depends on heat-
dependent release and not simply on attachment to the
outer surface of the vesicle. The fibrinolytic efficiency of
these liposomes is improved in the dynamic fibrinolytic assay
under conditions of permeation-driven fibrinolysis. Because
intravascular thrombi are exposed to permeation forces [40,
41], these properties of our construct suggest that it could be a
successful candidate as a therapeutic tool, the utility of which
deserves further investigation.
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